SlateStone Wealth LLC Makes New $658,000 Investment in Bristol Myers Squibb Company $BMY

SlateStone Wealth LLC bought a new position in Bristol Myers Squibb Company (NYSE:BMY) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 12,190 shares of the biopharmaceutical company’s stock, valued at approximately $658,000.

A number of other hedge funds have also added to or reduced their stakes in BMY. Brighton Jones LLC increased its holdings in Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after purchasing an additional 4,935 shares in the last quarter. Sivia Capital Partners LLC increased its holdings in Bristol Myers Squibb by 59.4% in the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock worth $346,000 after purchasing an additional 2,786 shares in the last quarter. United Bank increased its holdings in Bristol Myers Squibb by 15.0% in the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock worth $1,164,000 after purchasing an additional 3,277 shares in the last quarter. Marshall Wace LLP bought a new stake in Bristol Myers Squibb in the second quarter worth approximately $221,000. Finally, Nebula Research & Development LLC bought a new stake in Bristol Myers Squibb in the second quarter worth approximately $405,000. 76.41% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on BMY shares. Morgan Stanley restated an “underweight” rating and set a $40.00 price objective on shares of Bristol Myers Squibb in a report on Friday, February 6th. Bank of America decreased their price objective on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a report on Thursday, April 9th. Piper Sandler restated an “overweight” rating and set a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. UBS Group restated a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Finally, Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Eight analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $61.31.

Bristol Myers Squibb Trading Up 1.1%

NYSE BMY opened at $57.24 on Friday. The company has a market cap of $116.88 billion, a price-to-earnings ratio of 16.08, a P/E/G ratio of 0.16 and a beta of 0.24. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The business has a 50 day moving average price of $58.10 and a 200-day moving average price of $56.52. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.16. The company had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.Bristol Myers Squibb’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities analysts expect that Bristol Myers Squibb Company will post 6.32 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president owned 159,248 shares of the company’s stock, valued at $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.05% of the stock is currently owned by insiders.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The European Commission approved Opdivo plus AVD as the first immunotherapy-based frontline regimen for previously untreated stage III or IV classical Hodgkin lymphoma in the EU, which could expand Bristol Myers Squibb’s reach in a key oncology market. How Investors May Respond To Bristol Myers Squibb (BMY) Winning EU Nod For First-Line Opdivo Regimen
• Positive Sentiment: At ASCO 2026, Bristol Myers Squibb highlighted promising late-stage cancer data, including Phase 3 results for mezigdomide in relapsed or refractory multiple myeloma and survival data for izalontamab brengitecan, reinforcing the company’s pipeline momentum. Bristol-Myers Squibb Cancer Wins Test Investor Patience On Valuation
• Positive Sentiment: Arcus Biosciences and Bristol Myers Squibb expanded their kidney cancer collaboration to advance casdatifan combinations in ccRCC, giving BMY another clinical-development opportunity in oncology. Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
• Neutral Sentiment: Several articles noted that Bristol Myers Squibb remains attractive to value and dividend-focused investors, with commentary pointing to its yield and dividend durability rather than a major near-term catalyst. Billionaire Izzy Englander Just Made a Big Bet on This Beaten-Down High-Yield Dividend Stock
• Neutral Sentiment: Bristol Myers Squibb also drew attention from an options-volume report, suggesting heightened trading interest, though the item did not point to a specific fundamental driver. Bristol Myers Squibb Sees Unusually High Options Volume (NYSE:BMY)

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.